Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Sherlock Biosciences, a US-based home diagnostics technology developer exploiting Harvard University research, has received $80m in series B funding from a consortium led by Novalis LifeSciences. The round featured Illumina Ventures, the venture capital fund backed by genomics technology producer Illumina, as well as Albany Capital, Catalio Capital Management and existing investors including Northpond Ventures and Good Ventures. The company’s funding stands at $111m since it was founded in 2019. Sherlock had secured $31m in a series A round…